Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Stelzer Laurie Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 4 Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 22,297 shares @ $37, valued at $825k
06/12/2023 4 Stelzer Laurie (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.
Txns: Granted 21,500 options to buy @ $5.59, valued at $120.2k
06/02/2023 4 Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Sold 4,647 shares @ $37.06, valued at $172.2k
01/24/2023 4 Stelzer Laurie (CFO) has filed a Form 4 on Mirati Therapeutics, Inc.
Txns: Granted 26,864 shares @ $0
Granted 45,456 options to buy @ $45.66, valued at $2.1M
06/10/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/06/2022 4 Stelzer Laurie (Director) has filed a Form 4 on PMV Pharmaceuticals, Inc.
Txns: Granted 19,500 options @ $13.56, valued at $264.4k
06/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/16/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
03/11/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/05/2022 4 Stelzer Laurie (EVP & CFO) has filed a Form 4 on ARENA PHARMACEUTICALS INC
Txns: Granted 21,462 shares @ $0
06/10/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/09/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/03/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/24/2020 3 Form 3 - Initial statement of beneficial ownership of securities:
06/12/2020 4 Stelzer Laurie (Director) has filed a Form 4 on Surface Oncology, Inc.
Txns: Granted 12,000 options to buy @ $4.35, valued at $52.2k
03/17/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2020 3 Form 3 - Initial statement of beneficial ownership of securities:
02/24/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/18/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/13/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/12/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/04/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/17/2019 4 Stelzer Laurie (SVP, CFO) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Paid exercise price by delivering 3,408 shares @ $15.73, valued at $53.6k
Exercised 6,875 restricted stock units @ $0
06/06/2019 4 Stelzer Laurie (Director) has filed a Form 4 on Surface Oncology, Inc.
Txns: Granted 12,100 options to buy @ $3.69, valued at $44.6k
02/22/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/15/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/14/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/05/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/18/2018 4 Stelzer Laurie (SVP, CFO) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Paid exercise price by delivering 3,254 shares @ $19.02, valued at $61.9k
Exercised 6,875 restricted stock units @ $0
04/18/2018 3 Stelzer Laurie (Director) has filed a Form 3 on Surface Oncology, Inc.
02/23/2018 4 Stelzer Laurie (SVP, CFO) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Paid exercise price by delivering 3,939 shares @ $19.28, valued at $75.9k
Exercised 11,392 restricted stock units @ $0
02/16/2018 4 Stelzer Laurie (SVP, CFO) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Granted 54,780 options to buy @ $18.41, valued at $1M
Granted 31,234 restricted stock units @ $0
02/05/2018 4 Stelzer Laurie (SVP, CFO) has filed a Form 4 on HALOZYME THERAPEUTICS INC
Txns: Paid exercise price by delivering 8,265 shares @ $18.37, valued at $151.8k
Exercised 23,120 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy